

BPI INVEST GLOBAL HEALTH CARE FEEDER FUND

KEY INFORMATION AND INVESTMENT DISCLOSURE STATEMENT

As of May 31, 2022

FUND FACTS

Classification: Global Equity Feeder Fund

Launch Date: February 1, 2021

USD 1,000.00 **Minimum Investment:** Additional Investment: USD 500.00

Minimum Holding Period: None NAVPU: USD 83.70

Total Fund NAV (Mn): USD 6.66

Dealing Day: Daily up to 2:30 PM **Redemption Settlement:** T+5 End-of-Day

Early Redemption Charge:

None

None

FEES

Trustee Fees: 1.00% **Custodianship Fee: 0.00%**

BPI Asset Management None

As a percentage of average daily NAV for the quarter valued at USD 6.70 Million

Other Fees: 0.00% External Audit Fee: 0.00%

Isla Lipana

To be determined upon receipt

of billing

INVESTMENT OBJECTIVE AND STRATEGY

The Fund, operating as a Feeder Fund, intends to achieve for its Participants long term capital growth by investing in a Target Fund that invests in stocks in the health care sector. The Fund aims to provide excess return over the MSCI World Health Care Index. Pursuant to existing BSP rules and regulations, as a Feeder Fund, this Fund is mandated to invest at least 90% of its assets in a single collective investment scheme.

CLIENT SUITABILITY

A client profiling process shall be performed prior to participating in the Fund to guide the prospective investor if the Fund is suited to his/her investment objectives and risk tolerance. Clients are advised to read the Declaration of Trust/Plan Rules of the Fund, which may be obtained from the Trustee, before deciding to invest.

The BPI Invest Global Health Care Feeder Fund is for investors who:

- Are at least classified as aggressive based on their risk profile.
- Have an investment horizon of at least five (5) years.

Participation in the Fund shall be open to Participants with legal capacity to contract and who are not considered US persons under the US securities and tax laws, subject to the other conditions, rules or provisions stated in the Plan Rules and those established by the Trustee. No beneficial owner shall hold more than 10% of the Fund. Any investor who owns more than 10% shall be asked to redeem the amount (or its equivalent number of units) in excess of 10% within thirty (30) calendar days.

KEY RISKS AND RISK MANAGEMENT

You should not invest in this Fund if you do not understand or are not comfortable with the accompanying risks.

Market/Price Risk:

Investors are exposed to adverse changes in the prices of global equities in the health care sector due to adverse market conditions, unfavorable company earnings and valuations, and negative developments in the political and economic conditions of the focus countries of the securities of the target fund.

Investors are exposed to the risk of loss due to the target fund's inability to convert security holdings to cash Liquidity Risk: immediately or in instances where conversion to cash is possible but at a highly disadvantageous price due to limited participants in the market, low trading volumes, market disruptions, among others.

Country Risk:

Investors are exposed to the risk of loss arising from negative developments in the political, economic and social conditions of the focus countries of the underlying securities of the target fund, which may adversely affect the value of the feeder fund.

FX Risk:

Investors are exposed to the risk of loss from a decline in the market value of the target fund when the market value of foreign currency denominated securities held by the target fund are translated to USD.

The Fund's investment outlets undergo proper screening and evaluation in accordance with the Trustee's accreditation process. The Fund may also use financial derivatives to hedge the portfolio against market and credit risks.

- THE UIT FUND IS NOT A DEPOSIT AND IS NOT INSURED BY THE PHILIPPINE DEPOSIT INSURANCE CORP. (PDIC).
- RETURNS CANNOT BE GUARANTEED AND HISTORICAL NAVPU IS FOR ILLUSTRATION OF NAVPU MOVEMENTS/ FLUCTUATIONS ONLY.
- WHEN REDEEMING, THE PROCEEDS MAY BE WORTH LESS THAN THE ORIGINAL INVESTMENT AND ANY LOSSES SHALL BE SOLELY FOR THE ACCOUNT OF THE CLIENT.
- THE TRUSTEE IS NOT LIABLE FOR ANY LOSS UNLESS UPON WILLFUL DEFAULT, BAD FAITH OR GROSS **NEGLIGENCE.**

For more information, you may contact us at (632) 8580-AMTC (2682), email us at bpi_asset_management@bpi.com.ph or visit our website, www.bpiassetmanagement.com.

I DIND FERI CIRMANC	E AND S	TATISTIC	S AS OF	MAY 31, 2	2022		
(Purely for reference pu	ırposes ar	nd is not a	guarante	e of future	results)		
NAVPU GRAPH	•					NAVPu over the past 12	? months
120				. ^.		Highest	104.45
110	-	~~ ~	www	Jan Jan	1	Lowest	78.73
100	~~~	\~~\.		_		STATISTICS	76.76
90		_	~~~		, no.	Volatility, since inception	(%) ⁴ 16.44
70 — Fund =	Bench	ımark*				Sharpe Ratio ⁵	-0.90
	ep-21 N	lov-21	Jan-22	Mar-22	May-22	Information Ratio ⁶	-0.90 -1.13
*MSCI World Health Care	Index						1.10
CUMULATIVE PERFO	RMANCE	(%)1				¹ Returns are net of fees.	
1 mc		6 mos	1YR	3YRS	S.I. ²	² Since Inception ³ Fund performance from	Eah to year and 2021
Fund -0.72		-12.52	-14.57		-16.30		which the Fund fluctuates vis-à-
Benchmark 0.49		-2.15	3.97	-	9.41	vis its average return ove	
ANNUALIZED PERFO		<u> </u>	4YRS	5YR	S.I. ²		w well the return of a Fund
Fund -14.5		-	-		-12.56	compensates the investo higher the number, the be	r for the level of risk taken. The
Benchmark 3.97		_	-	-	7.02		c efficiency of the portfolio
CALENDAR YEAR PE		ANCE (%)	1				The higher the number, the
YTD	2021 ³					higher the reward per uni	
Fund -15.5	7 -0.86						vailable upon request through
Benchmark -7.38						your branch of account.	
PORTFOLIO COMPO	SITION				_		
Allocation				% of F			
Target Fund				99.05		TOP TEN HOLDINGS	
Cash and Equivalents Others – net of liabilitie	<u> </u>			1.08 -0.13		Name	% of Target Fund
Regional Breakdowr			9/	6 of Targ		UnitedHealth Group	8.15
United States	<u> </u>			74.97		Eli Lily & Co.	7.07
United Kingdom				7.46			
United Kingdom Japan				7.46 5.17		Pfizer Inc.	6.35
						Pfizer Inc. AstraZeneca Plc.	6.35 4.78
Japan Others Sector Breakdown			q	5.17 12.40 % of Targ e) et Fund	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb	6.35 4.78 3.41
Japan Others Sector Breakdown Major Pharmaceutical	S		C .	5.17 12.40 % of Targ e 25.98	et Fund	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG	6.35 4.78 3.41 3.33
Japan Others Sector Breakdown Major Pharmaceutical Health Services	s		C	5.17 12.40 % of Targ o 25.98 17.56	et Fund	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG Danaher Corp.	6.35 4.78 3.41 3.33 2.94
Japan Others Sector Breakdown Major Pharmaceutical Health Services Biotechnology	S		C	5.17 12.40 % of Targ 25.98 17.56 16.41	et Fund	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG Danaher Corp. Humana Inc.	6.35 4.78 3.41 3.33 2.94 2.93
Japan Others Sector Breakdown Major Pharmaceutical Health Services Biotechnology Medical Technology	S		C	5.17 12.40 % of Targo 25.98 17.56 16.41	et Fund	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG Danaher Corp. Humana Inc. Vertex Pharmaceutica	6.35 4.78 3.41 3.33 2.94 2.93 2.67
Japan Others Sector Breakdown Major Pharmaceutical Health Services Biotechnology	s		C	5.17 12.40 % of Targ 25.98 17.56 16.41	et Fund	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG Danaher Corp. Humana Inc.	6.35 4.78 3.41 3.33 2.94 2.93
Japan Others Sector Breakdown Major Pharmaceutical Health Services Biotechnology Medical Technology	S		Ç	5.17 12.40 % of Targo 25.98 17.56 16.41	et Fund	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG Danaher Corp. Humana Inc. Vertex Pharmaceutica	6.35 4.78 3.41 3.33 2.94 2.93 2.67
Japan Others Sector Breakdown Major Pharmaceutical Health Services Biotechnology Medical Technology		ONS*	C	5.17 12.40 % of Targo 25.98 17.56 16.41	et Fund	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG Danaher Corp. Humana Inc. Vertex Pharmaceutica	6.35 4.78 3.41 3.33 2.94 2.93 2.67
Japan Others Sector Breakdown Major Pharmaceutical Health Services Biotechnology Medical Technology Others RELATED PARTY TRA	ANSACTI			5.17 12.40 % of Targe 25.98 17.56 16.41 15.06 24.99	et Fund 3 5 1 6 9	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG Danaher Corp. Humana Inc. Vertex Pharmaceutica Daiichi Sankyo Co	6.35 4.78 3.41 3.33 2.94 2.93 2.67
Japan Others Sector Breakdown Major Pharmaceutical Health Services Biotechnology Medical Technology Others RELATED PARTY TRA The Fund has no transa	ANSACTIO	d outstand	ding inves	5.17 12.40 % of Targe 25.98 17.56 16.41 15.06 24.99	et Fund 3 5 1 5 9	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG Danaher Corp. Humana Inc. Vertex Pharmaceutica Daiichi Sankyo Co	6.35 4.78 3.41 3.33 2.94 2.93 2.67 2.49
Japan Others Sector Breakdown Major Pharmaceutical Health Services Biotechnology Medical Technology Others RELATED PARTY TRA The Fund has no transa (BPI AMTC).	ANSACTI actions an	d outstand	ding inves	5.17 12.40 % of Targe 25.98 17.56 16.41 15.06 24.99	et Fund 3 5 1 5 9	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG Danaher Corp. Humana Inc. Vertex Pharmaceutica Daiichi Sankyo Co	6.35 4.78 3.41 3.33 2.94 2.93 2.67 2.49
Japan Others Sector Breakdown Major Pharmaceutical Health Services Biotechnology Medical Technology Others RELATED PARTY TRA The Fund has no transa (BPI AMTC). * Related party in accor	ANSACTI actions an	d outstand	ding inves	5.17 12.40 % of Targe 25.98 17.56 16.41 15.06 24.99	et Fund 3 5 1 5 9	Pfizer Inc. AstraZeneca Plc. Bristol Myers Squibb Novartis AG Danaher Corp. Humana Inc. Vertex Pharmaceutica Daiichi Sankyo Co	6.35 4.78 3.41 3.33 2.94 2.93 2.67 2.49

Fund Manager: Wellington Management Company LLP The Fund Performance Report and relevant information about the Victorians and the Victorians and Victorians

Central Bank of Ireland

Fund

Name of Target Fund:

Regulator:

Wellington Global Health Care Equity

The Fund Performance Report and relevant information about the Wellington Global Health Care Equity Fund can be viewed and downloaded through https://www.wellingtonfunds.com/en-at/institutional/.

Custodian:

Total Expense Ratio:

State Street Custodial Services

(Ireland) Limited

1.32%

OUTLOOK AND STRATEGY

Market Review. Global equity markets continued to be volatile in May as tightening monetary policy, inflation concerns and geopolitical tensions continued to dominate headlines. Global central banks continued their hawkish stance to curb high inflation. The Federal Reserve raised interest rates by half a percentage point and announced the start of quantitative tightening in June. Inflationary pressures remained and global economies are still posting their multi-year inflation highs. Crude prices soared as EU leaders agreed to ban imports of Russian oil as part of their sanctions package. In China, sentiment improved as officials announced the reopening of Shanghai and unveiled a list of measures to boost the economy.

The MSCI World Health Care Index returned 0.5% for the month, led by large-cap biopharmaceuticals and health care services.

Fund Performance: The fund returned -0.72% in May, lagging the benchmark by 121 basis points. Security selection detracted from performance.

Fund Strategy. COVID-19 disruptions will likely continue for many months, but we are encouraged by strong fundamentals across the healthcare industry, leading the way to a more normalized investment backdrop. Attractive valuations and breakthrough innovations in the biopharma industry are compelling and are creating a rich opportunity set for investors. Outside of biopharma, certain medical technology companies are seeing strong fundamentals as they help enable robust drug development and manufacturing in diverse therapeutic categories. COVID-19 testing, development of more convenient routine medical tests and expansion into new attractive categories, such as early cancer screening, should provide support for the diagnostics industry. Within procedure-oriented subsectors, medical devices are expected to experience increase in demand as patients resume elective procedures. These tailwinds across the various healthcare subsectors, coupled with strong valuation support leaves us with a positive outlook in 2022. The fund will continue to favor companies that develop innovative products designed to address important unmet medical needs. Over the long term, the tailwinds of innovation, an aging population and the globalization of demand cutting-edge Western-style medicines should continue to drive growth for the sector.

LIST OF PROSPECTIVE INVESTMENTS

The following are among the Fund's approved investment outlets, wherein the Trustee intends to invest depending on strategy, availability, or other market-driven circumstances:

- (a) Primarily in a single collective investment scheme whose investment objective is to provide investment results in excess of the return of the MSCI World Health Care Index; provided further that such CIS is approved or registered and supervised by a regulatory authority that is a member of the International Organization of Securities Commissions (IOSCO) and managed by reputable fund manager/s; provided further that the investment in the said collective investment scheme should at least be ninety percent (90%) of the total assets of the Fund. The Target Fund must be recognized as a collective investment scheme in its home jurisdiction by a regulatory authority or any regulatory authority acceptable to the BSP to supervise this CIS.
- (b) Short-term tradable fixed-income instruments issued or guaranteed by the Philippine government or the BSP; tradable securities issued by the government of a foreign country, any political subdivision/agency of a foreign country or any supranational entity; tradable fixed-income instruments issued by foreign or local financial institutions or private corporations; exchange- listed securities; marketable instruments that are traded in an organized exchange; loans traded in an organized market; and, such other tradable investments outlets/ categories as the BSP may allow. Provided, that, a financial instrument is regarded as tradable if two-way prices are quoted, readily available or regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.
- (c) Short-term tradable fixed-income instruments issued, underwritten, or otherwise dealt by BPI and/or any of its subsidiaries, affiliates, their successors-in-interest or assignees, their directors, officers, stockholders, and related interest, and any of their trust and fund managed accounts, under such terms and conditions as the Trustee may deem to be in the best interest of the Fund; and, any such other instruments as may be allowed under BSP regulations. Investment with related interests shall be in accordance with Section 414-Q of the Manual of Regulations for Non-Bank Financial Institutions.
- (d) The principal investments of the Fund will be denominated in, but not limited to the U.S. Dollar. The target fund invests in securities denominated in other currencies.
- (e) Bank deposits or tradable debt instruments issued by the BSP.
- (f) Such other investments allowed under regulations issued by the BSP.

INVESTMENT OBJECTIVE OF TARGET FUND

The Wellington Global Health Care Equity Fund seeks long-term total returns. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of health care companies worldwide. The Fund takes a long term value approach and seeks to invest in fundamentally sound companies. Although the Fund is not constructed relative to a benchmark, the MSCI World Health Care index will serve as a reference benchmark.

BPI Asset Management and Trust Corporation (BPI AMTC) is a subsidiary of the Bank of the Philippine Islands. For inquiries and comments, please send an email to bpi_asset_management@bpi.com.ph or call us at (02) 8580-AMTC (2682).

Regulated by the Bangko Sentral ng Pilipinas. https://www.bsp.gov.ph, BSP Webchat https://www.bsp.gov.ph

SMS: 021582277 & BSP CAMS Facebook https://www.facebook.com/BangkoSentraIngPilipinas